The Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect and in partnership with MTAA and others, is a $19.75 million Medical Research Future Fund initiative. The CTCM program identifies and nurtures high-quality medical device projects that have commercial potential and supports their translation through early clinical trials. By championing Australian SMEs along the commercialisation journey, the CTCM program is improving the health and well-being of Australians while supporting the Australian medical products sector.
The Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect, is offered under the 2020 Early Stage Translation and Commercialisation Support Grant of the Medical Research Future Fund's Medical Research Commercialisation Initiative.
The $19.75 million program will identify and nurture high-quality medical device projects that have commercial potential and support their translation through early clinical trials. The program is focused on Australian small to medium-sized enterprises (SMEs) and aims to boost commercialisation of home-grown medical products.
Projects must focus on the development of a medical device for human use, the purpose of which is to diagnose, prevent, monitor, treat or alleviate a disease or injury, or modify or monitor anatomy or physiological functions of the body. Funding will only be awarded to projects where the device’s capability has already been validated with research and/or preclinical studies.
By providing funding of between $250,000 and $1.5 million per project across two funding rounds (FY2022 and FY2023), the CTCM Program will:
- Deliver consultation and commercialisation advice to guide project development and assessment
- Facilitate access to broader NCRIS and other critical engineering, fabrication and prototyping facilities to accelerate translation of early-stage discoveries
- Emphasise collaboration, partnering and consultation to nurture the next generation of health and medical research innovators and provide ongoing SME education
- Employ a process of continuous evaluation, based on established commercial principles, to optimise the potential for project success and maximise return on investment.
By supporting the development of innovative medical devices, the CTCM program aims to improve the health and wellbeing of Australians, while also helping projects to generate commercial returns and create high-paying jobs in the medical products sector.
MTPConnect is delivering the program in partnership with MTAA and other highly esteemed medical technology commercialisation, education and infrastructure partners: Medical Device Partnering Program (MDPP), Cicada Innovations, the BridgeTech Program and Therapeutic Innovation Australia (TIA).
